Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
Replimune Group, Inc. announced receiving a Complete Response Letter from the FDA regarding its Biologics License Application for RP1 combined with nivolumab to treat advanced melanoma. The FDA did not approve the application citing concerns despite previous breakthrough therapy designation and positive trial results. The company expressed disappoi…